tolbutamide has been researched along with exenatide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahekar, RH; Goel, A; Gupta, AA; Jadav, PA; Jain, MR; Patel, DN; Patel, PR; Prajapati, VM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egido, EM; Hernández, R; Marco, J; Silvestre, RA | 1 |
| Heller, C; Kühn, MC; Mülders-Opgenoorth, B; Scherbaum, WA; Schinner, S; Schott, M; Willenberg, HS | 1 |
| Biernath, A; Forschler, F; Frey, O; Hierlemann, A; Misun, PM; Neelakandhan, A; Rousset, N; Yesildag, B | 1 |
1 review(s) available for tolbutamide and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for tolbutamide and exenatide
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidines.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Glucose; Guanidines; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Secretion; Insulin-Secreting Cells; Insulinoma; Molecular Structure; Pyridines; Rats; Stereoisomerism | 2007 |
Tungstate stimulates insulin release and inhibits somatostatin output in the perfused rat pancreas.
Topics: Animals; Arginine; Cysteamine; Exenatide; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Male; Pancreas; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Tolbutamide; Tungsten Compounds; Venoms | 2005 |
Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.
Topics: Animals; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Mice; Mice, Inbred C57BL; Peptides; Receptors, Glucagon; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tolbutamide; Up-Regulation; Venoms; Wnt4 Protein | 2011 |
In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution.
Topics: Diabetes Mellitus, Type 2; Drug Discovery; Exenatide; Glucose; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Microfluidic Analytical Techniques; Models, Biological; Tissue Array Analysis; Tolbutamide | 2020 |